The addition of the immune checkpoint inhibitor Tecentriq (atezolizumab) to neoadjuvant chemotherapy and as a single agent ...
BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology ...
Roche has announced that its phase 3 IMpower130 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) in non-small cell lung cancer (NSCLC). The combination ...
Roche’s Tecentriq has been added to the new-look Cancer Drugs Fund for bladder cancer patients, making it the latest in a recent flurry of drugs to be put on the managed access fund. Overseen by ...
A tumor-informed ctDNA assay identified MRD in TNBC patients, indicating a 30-fold higher risk of distant recurrence for MRD-positive individuals. The NSABP B-59/GBG 96-GeparDouze trial involved 1550 ...
Overall survival was twice as long for people treated with Columvi in combination with GemOx versus MabThera/Rituxan plus ...
Data presented at ASH suggested that CDK4/6 inhibitors given with chemo for Rb-deficient tumors could mitigate the risk of secondary myeloid neoplasms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback